Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
51.75 EUR | +0.49% | +3.00% | -30.41% |
Jun. 24 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
Jun. 17 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.41% | 6.6B | - | ||
+20.17% | 126B | B+ | ||
+24.67% | 118B | B+ | ||
+23.96% | 27.87B | B | ||
-17.74% | 20.95B | B+ | ||
-15.22% | 16.92B | A- | ||
-15.21% | 16.18B | B | ||
+11.91% | 14.84B | C+ | ||
-47.10% | 14.79B | A- | ||
+54.50% | 14.08B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CYTK Stock
- KK3A Stock
- Ratings Cytokinetics, Incorporated